Introduction:
Multiply Labs, in collaboration with UCSF, Cytiva, Thermo Fisher Scientific, and Charles River Laboratories, has developed a robotic system for automated cell therapy manufacturing. The company has reported performance results that demonstrate the statistical equivalency of automated cell therapy manufacturing outcomes to manually performed processes, without significant changes to the process or product characteristics.
- The automated cell therapy manufacturing outcomes using Multiply Labs’ robotic system are statistically equivalent to manually performed processes.
- The robotic technology is compatible with leading cell therapy manufacturing instruments, allowing for the automation of existing cell expansion protocols.
- The automation of cell therapy manufacturing processes has the potential to decrease labor costs and increase manufacturing throughput.
- The robotic system’s ability to culture T cells was assessed in parallel with manual conditions, and the cell quantity, viability, and gene expression analyses were found to be statistically indistinguishable.
- The robotic system has the advantage of reducing bioprocess and regulatory risks and preventing microbial contamination.
Conclusion:
The performance results of Multiply Labs’ robotic system for automated cell therapy manufacturing show that it is possible to automate existing cell expansion protocols without significant modifications to the process or impacting product characteristics. This automation has the potential to decrease labor costs, increase manufacturing throughput, and improve patient access to cell therapies. Further research and development in automation technologies could lead to the automation of the entire end-to-end cell therapy manufacturing process.
